Parsey Merdad 4

What Happened

• Parsey Merdad, a director of ArriVent BioPharma, was granted a derivative award covering 13,562 shares on June 18, 2026. The award was reported at $0.00 per share (derivative security) — this is an equity grant/award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18
• Filing date: 2026-06-22 (Form 4 accession 0001104659-26-076570)
• Transaction type/code: Award/Grant (A), derivative
• Number of shares/units: 13,562
• Reported price: $0.00 (no cash paid at grant)
• Shares owned after transaction: Not disclosed in the filing
• Footnote: F1 — "The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date."
• Timeliness: Filing appears timely (filed within required reporting window)

Context

• This was an equity compensation grant (derivative award) that vests one year after the grant date if the director remains in service. It does not represent an immediate purchase or sale of shares and does not indicate shares were exercised or sold. Such awards are commonly used for compensation and retention.